Since human carcinomas circumvent senescence and inhibitory pathways of proliferation induced by DNA damage, through the upregulation of telomerase activity [15], downregulation of LRP with subsequent suppression of telomerase activity is therefore another way in which LRP/LR can be targeted as a potential therapeutic intervention for cancer. Here, RPSA is linked to carcinoma.